Adenocarcinoma of the Prostate: Diagnosis & Treatment

Adenocarcinoma of the prostate is the most common form of prostate cancer, accounting for the vast majority of cases. Diagnosing it involves a layered process that starts with blood tests and imaging and often ends with a tissue biopsy, while treatment spans a surprisingly wide range, from doing nothing immediately to radioactive drugs that hunt tumor cells throughout the body. The choices at each stage depend heavily on how aggressive the cancer appears under a microscope and how far it has spread, making the grading and staging steps just as important as the treatment itself.

PSA Screening and What It Actually Tells You

Most prostate adenocarcinomas are first suspected because of an elevated prostate-specific antigen (PSA) level in a blood test, sometimes paired with an abnormal digital rectal exam. PSA is a protein produced by both normal and cancerous prostate tissue, so a high reading does not automatically mean cancer. Infections, an enlarged prostate, and even vigorous exercise can push the number up.

The value of routine PSA screening has been debated for decades. A large systematic review and meta-analysis found that screening probably has no effect on dying from any cause and may reduce prostate-cancer-specific death by roughly one fewer death per 1,000 men screened over ten years. At the same time, modeling from the same analysis estimated that for every 1,000 men screened, about 25 more would report erectile dysfunction and about 3 more would need pads for urinary incontinence as a result of downstream biopsies and treatments.¹ Those numbers illustrate why guidelines now favor shared decision-making rather than blanket screening for all men.

Risk-stratified screening, which adjusts how often you get tested based on your baseline PSA level, may help trim the downsides. Modeling studies suggest that spacing screening intervals out to every eight years when a man’s PSA is very low at age 45 could cut the number of tests by almost half while barely reducing the number of lives saved.² The practical takeaway is that a single PSA number is a starting point for conversation, not a diagnosis.

MRI Before the Needle

When PSA or a physical exam raises concern, the next step increasingly involves multiparametric MRI of the prostate rather than jumping straight to a biopsy. MRI can reveal suspicious areas and help doctors decide whether a biopsy is warranted at all. A meta-analysis of studies using the PI-RADS scoring system found pooled sensitivity around 78% and specificity around 79% for detecting prostate cancer, with those numbers climbing to about 82% for both when PI-RADS criteria were applied correctly.³ A separate meta-analysis reported specificity of 88% and sensitivity of 74%, with negative predictive values high enough to suggest MRI could help spare some men from unnecessary biopsies.⁴

This means MRI catches most clinically significant cancers, though it is not perfect. Small or diffuse tumors can be missed, and the quality of the scan depends heavily on the machine and the radiologist reading it. For lesions scored as highly suspicious (PI-RADS 5), MRI-targeted biopsy alone detected clinically significant cancer in about 68% of cases, matching the detection rate of targeted plus systematic biopsy combined. Using targeted biopsy alone would have avoided roughly 41% of unnecessary systematic biopsies without missing significant disease.⁵

Biopsy Routes and Infection Risk

If imaging warrants it, a tissue sample is taken via needle biopsy. Two main routes exist: through the rectum (transrectal) or through the perineum, the skin between the scrotum and the rectum (transperineal). A systematic review and meta-analysis of randomized controlled trials found no significant difference in overall cancer detection rates between the two approaches.⁶ A separate meta-analysis confirmed similar diagnostic accuracy but noted a lower complication risk with the transperineal route.⁷

Infection is the main safety concern. One tertiary-center study reported a urinary tract infection rate of about 4% after transrectal biopsy compared with roughly 1% after transperineal biopsy.⁸ Because the transperineal route avoids passing a needle through the rectal wall, it sidesteps many gut bacteria, which is why centers worldwide have been shifting toward it. Both approaches are generally safe, and serious complications like sepsis requiring hospitalization remain uncommon.

How Prostate Cancer Is Graded and Staged

Once tissue is obtained, a pathologist assigns a grade that reflects how abnormal the cells look. The current standard is the ISUP Grade Group system, which ranges from 1 (least aggressive) to 5 (most aggressive). This system replaced the older three-tier Gleason grouping because it separates risk categories more clearly. A study of over 2,000 men showed that ISUP grade on needle biopsy was significantly associated with tumor volume, pathological stage, and the likelihood of cancer recurrence after surgery.⁹ An independent validation in men treated with radiation confirmed that each step up in grade group carried a progressively worse outlook: compared with Group 1, the risk of dying from prostate cancer was about three times higher for Group 2 and roughly 39 times higher for Group 5.¹⁰

Staging adds information about whether the cancer has spread beyond the prostate. For men with higher-risk disease, PSMA PET/CT scans have become a game-changer. This imaging technique uses a radioactive tracer that binds to prostate-specific membrane antigen on cancer cells, lighting them up on a full-body scan. It outperforms older imaging methods like bone scans and CT for detecting spread to lymph nodes and distant sites, and it changes the management plan in roughly one out of four patients compared with conventional imaging.¹¹ That said, it is not infallible: for lymph node detection specifically, sensitivity ranges from about 53% to 67% depending on how thoroughly the lymph nodes are sampled at surgery.¹²

Active Surveillance for Low-Risk Disease

Not every prostate adenocarcinoma needs immediate treatment. For men with Grade Group 1 cancer and low PSA, active surveillance has become the preferred approach. This means regular PSA checks, periodic MRI, and occasional repeat biopsies, with treatment triggered only if the cancer shows signs of becoming more aggressive.

The safety record is strong. A large cohort at Memorial Sloan Kettering found that men with Grade Group 1 disease on active surveillance had a ten-year prostate cancer-specific survival of essentially 100%, with a distant metastasis rate of just 0.6% at ten years. About 64% of men remained treatment-free at the decade mark.¹³ A multi-institutional study reported similar findings: at ten years, the rate of metastasis or prostate cancer death was about 1.4%, and roughly half of the men had eventually moved to treatment, usually because a repeat biopsy showed the grade had worsened.¹⁴ Reviews covering multiple surveillance programs report cancer-specific mortality of around 0.5% to 3% at 10 to 15 years.¹⁵

The key point for patients is that “surveillance” is not the same as “doing nothing.” It involves a structured monitoring protocol, and the option to treat remains open if the cancer changes character.

Surgery Versus Radiation for Localized Cancer

When treatment is warranted for cancer confined to the prostate, the two main curative options are radical prostatectomy (surgery to remove the gland) and radiation therapy (either external-beam radiation or brachytherapy seeds implanted into the prostate). Both can cure the disease, and choosing between them involves weighing side-effect profiles, a man’s age, and the cancer’s aggressiveness.

Observational data paint a complicated picture. One population-based study using matched cohorts found no significant difference in cancer-specific survival between surgery and radiation, though overall survival favored surgery; among younger men, both outcomes were statistically similar.¹⁶ A larger observational study found that after adjusting for patient differences, radiation was still associated with higher prostate-cancer mortality than surgery across all risk groups for non-metastatic disease.¹⁷ For men with very-high-risk disease, one analysis found five-year cancer-specific mortality of about 3.5% after surgery versus 6% after radiation.¹⁸

These are observational comparisons, not randomized trials, so the numbers are affected by the types of patients who tend to choose each treatment. The broad clinical consensus is that both modalities offer excellent cancer control for most localized disease, and the decision often comes down to which side effects a man is more willing to accept. Surgery carries a higher risk of urinary incontinence and erectile dysfunction up front, while radiation can cause bowel irritation and erectile problems that develop more gradually.

Focal Therapy as a Middle Ground

Focal therapy aims to destroy only the tumor within the prostate, leaving healthy tissue intact. Techniques include high-intensity focused ultrasound (HIFU), cryotherapy, and irreversible electroporation. A systematic review and meta-analysis of 49 focal-therapy cohorts reported pooled overall survival of 98%, cancer-specific survival over 99%, and a pooled rate of clinically significant cancer found on follow-up biopsy of about 22% overall, though only about 9% within the treated zone itself.¹⁹ About 10.5% of men ultimately needed full radical treatment.

Where focal therapy really shines is in preserving quality of life. A separate systematic review covering over 6,900 patients found that post-operative pad-free rates ranged from about 92% to 100%, meaning almost no one had significant incontinence.²⁰ Erectile function results were more variable, with preservation rates ranging widely depending on the technique. Focal therapy is most appropriate for men with well-localized, intermediate-risk disease and is still considered investigational in many guidelines, meaning long-term data beyond ten years remain limited.

Hormone Therapy and Cardiovascular Considerations

Prostate adenocarcinoma relies on androgens, particularly testosterone and its more potent derivative, to fuel growth. Androgen deprivation therapy (ADT) cuts off that fuel supply and forms the backbone of treatment for advanced disease. Castration-resistant disease, which is cancer that progresses despite very low testosterone levels, develops because tumor cells find workarounds, including overexpressing the androgen receptor, producing splice variants that signal without testosterone, or even manufacturing their own androgens internally.²¹

ADT is delivered primarily through two drug classes: GnRH agonists and GnRH antagonists. Both suppress testosterone to castrate levels, but they differ in cardiovascular safety. A systematic review found that GnRH antagonists were associated with roughly half the rate of cardiovascular events compared with agonists.²² A Bayesian analysis across trials found a similar pattern, with antagonists showing a pooled odds ratio of about 0.57 for major cardiovascular events compared with agonists.²³ One hypothesis is that agonists cause an initial surge in hormones, including follicle-stimulating hormone, that may stress the cardiovascular system, while antagonists suppress hormones immediately without that spike.²⁴ These findings deserve caution because cardiovascular events were secondary endpoints in most of the underlying trials, but they are increasingly influencing drug selection, especially for men who already have heart disease.

Combination Therapy for Metastatic Hormone-Sensitive Disease

When prostate cancer has spread but still responds to hormone suppression, ADT alone is no longer considered enough. Multiple large randomized trials have shown that adding a second agent significantly extends survival. A review of the evidence concluded that adding an androgen receptor pathway inhibitor and/or docetaxel chemotherapy to ADT meaningfully improves outcomes.²⁵

Enzalutamide, one such agent, illustrates the benefit. In a major trial, adding it to standard first-line therapy reduced the risk of death by about a third. Three-year overall survival was 80% with enzalutamide versus 72% without it.²⁶ Extended follow-up at about five and a half years confirmed a durable benefit, with five-year overall survival of 67% with enzalutamide compared to 57% with standard care alone.²⁷ These results, replicated with other drugs in the same class, have fundamentally changed the standard of care. ADT monotherapy for metastatic disease is now widely regarded as insufficient.

When the Cancer Stops Responding to Hormones

Castration-resistant prostate cancer (CRPC) is the stage at which the disease progresses despite castrate levels of testosterone. It is not a single entity but a spectrum. Some tumors are still partially driven by the androgen receptor through the resistance mechanisms discussed earlier. Others evolve away from androgen dependence entirely, sometimes transforming into a neuroendocrine phenotype that no longer produces PSA and behaves quite differently.²⁸

Taxane chemotherapy remains important in this setting. Docetaxel was the first chemotherapy to show a survival benefit in CRPC, and cabazitaxel was developed as a follow-on option because it is less susceptible to the drug-efflux pumps that help tumors resist docetaxel.²⁹ In a head-to-head trial, cabazitaxel outperformed a second-line androgen-signaling inhibitor after prior docetaxel failure, extending median overall survival from 11 months to about 13.6 months.³⁰ Despite these gains, resistance still develops universally over time, which is why newer therapeutic classes are needed.³¹

PARP Inhibitors and the Role of Genetic Testing

One of the most significant advances in prostate cancer treatment has been the approval of PARP inhibitors, drugs that exploit weaknesses in a tumor’s ability to repair its own DNA. If a cancer cell already has a faulty DNA-repair gene, blocking the PARP enzyme as well can be lethal to it while sparing normal cells. Olaparib and rucaparib have been approved for men with metastatic CRPC whose tumors carry mutations in BRCA2, BRCA1, or other DNA-repair genes.³²

In the pivotal trial for olaparib, men with BRCA1/2 or ATM mutations saw median progression-free survival more than double compared with a control group: 7.4 months versus 3.6 months.³³ Not all mutations respond equally. BRCA2-altered tumors tend to respond much better than BRCA1-altered ones, with PSA response rates of about 63% versus 23%, and BRCA2 carriers had significantly longer overall survival on a PARP inhibitor.³⁴

These targeted therapies make genetic testing essential. Germline mutations in DNA-repair genes are found in up to roughly 12% of men with metastatic prostate cancer, compared with about 5% of men with localized disease. Carrying a BRCA2 mutation raises the risk of developing prostate cancer by about eightfold, and men with these mutations tend to be diagnosed with higher-grade, more advanced tumors and have shorter cancer-specific survival than non-carriers.³⁵ Guidelines now recommend germline testing for all men with metastatic prostate cancer, those with high-risk features, and men with strong family histories of cancer, both to guide their treatment and to identify hereditary cancer syndromes that may affect their relatives.³⁶

Radioligand Therapy With Lutetium-177 PSMA

For men with metastatic CRPC who have already been through hormonal agents and chemotherapy, a newer option is lutetium-177 PSMA-617, a radiopharmaceutical that delivers targeted radiation directly to cancer cells expressing PSMA. In the landmark VISION trial, adding it to standard care extended median overall survival from about 11.3 months to 15.3 months and more than doubled progression-free survival. Quality of life was not worsened despite a higher rate of side effects in the treatment arm.³⁷

Earlier-phase data had already been encouraging. In one study of 56 patients, 80% showed a PSA decline after treatment, and among those followed for at least six months after multiple cycles, molecular imaging showed partial remission in more than half. The most common side effect was mild dry mouth from radiation exposure to the salivary glands, and no significant drops in platelet counts were observed.³⁸ The treatment requires that a patient’s tumor takes up the PSMA tracer on a PET scan; men whose cancers do not express PSMA strongly enough are not good candidates. Research is now investigating whether moving lutetium-177 PSMA earlier in the treatment sequence could produce even larger benefits.

Racial Disparities in Incidence and Outcomes

Prostate cancer does not affect all populations equally. In the United States, Black men face the highest burden of any racial group, with an age-adjusted incidence rate of about 172 per 100,000 compared with roughly 98 per 100,000 for non-Hispanic White men and about 54 per 100,000 for Asian/Pacific Islander men. The disparity in mortality is even starker: Black men die of prostate cancer at more than twice the rate of White men and over four times the rate of Asian/Pacific Islander men.³⁹ These gaps reflect a tangle of factors including differences in access to screening and treatment, socioeconomic barriers, and biological differences in tumor biology and genetics. Understanding these disparities is important for patients and clinicians alike, because they influence how aggressively screening should be pursued in different populations.

Artificial Intelligence in Prostate Cancer Imaging

AI systems are beginning to change how prostate MRI is read. In a large international study comparing an AI system against 62 radiologists, the AI achieved a higher area under the curve (a measure of diagnostic accuracy) of 0.91 versus 0.86 for the radiologist pool. At the same specificity, the AI detected about 7% more clinically significant cancers, and at the same sensitivity, it halved the number of false-positive results.⁴⁰

When used as a decision-support tool rather than a replacement for the radiologist, the gains persist. A multireader study found that giving radiologists access to an AI assistant raised sensitivity from about 94% to 97% and improved specificity, with the biggest gains seen among less experienced readers.⁴¹ These tools are not yet standard at every institution, but they point toward a future where AI helps reduce the variability in MRI reads that currently contributes to missed cancers or unnecessary biopsies.

Metabolic Factors and Prostate Cancer Risk

There is a common perception that metabolic syndrome, the cluster of conditions including obesity, high blood pressure, and abnormal cholesterol, drives prostate cancer risk. The reality is more nuanced. A large UK Biobank study found that metabolic syndrome overall was not significantly associated with prostate cancer incidence. When the individual components were broken apart, obesity and hypertension were each modestly linked to a higher risk, while prediabetes or diabetes and low HDL cholesterol were associated with a slightly lower risk.⁴² The relationships go in different directions depending on the specific component, which is why lumping them together as “metabolic syndrome” obscures more than it reveals.

That said, the metabolic environment may matter more for cancer progression than for initiation. Obesity, insulin resistance, and the chronic inflammation they promote have been linked to prostate cancer progression through multiple overlapping pathways, including elevated insulin-like growth factor, abnormal levels of fat-derived hormones, and a shift in fatty acid metabolism within tumor cells. There is even a hypothesis that the lower testosterone levels associated with obesity could selectively favor more aggressive, androgen-independent cancer cells.⁴³ The practical message is that maintaining a healthy weight and staying physically active are unlikely to prevent prostate cancer outright but may influence how the disease behaves once it develops.